{"id":"didanosine-lamivudine-efavirenz","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Dizziness/CNS effects"},{"rate":"10-15","effect":"Rash"},{"rate":"1-2","effect":"Pancreatitis"},{"rate":"5-10","effect":"Hepatotoxicity"},{"rate":"10-15","effect":"Nausea"},{"rate":"variable","effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Didanosine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that compete with natural nucleotides to terminate viral DNA chain elongation. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds and inhibits the reverse transcriptase enzyme. Together, they suppress HIV viral load by targeting multiple steps of the viral replication cycle.","oneSentence":"This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes required for viral reproduction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:43.727Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00051090","phase":"NA","title":"Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B","enrollment":""},{"nctId":"NCT00001087","phase":"PHASE2","title":"The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00000885","phase":"PHASE2","title":"Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":440},{"nctId":"NCT00084136","phase":"PHASE4","title":"Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-05","conditions":"HIV Infections","enrollment":1571},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00000922","phase":"NA","title":"A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1710},{"nctId":"NCT00014937","phase":"NA","title":"Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00342355","phase":"PHASE4","title":"Antiretroviral Therapy for Advanced HIV Disease in South Africa","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2004-01","conditions":"HIV","enrollment":1771},{"nctId":"NCT00197613","phase":"PHASE3","title":"The Adult Antiretroviral Treatment and Resistance Study (Tshepo)","status":"COMPLETED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2002-12","conditions":"AIDS, HIV Infection","enrollment":650},{"nctId":"NCT00000919","phase":"NA","title":"A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":900},{"nctId":"NCT00000918","phase":"PHASE2","title":"A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00013520","phase":"PHASE3","title":"Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1125},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":"HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease","enrollment":80},{"nctId":"NCT00122538","phase":"PHASE2","title":"Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2006-02","conditions":"HIV Infections, AIDS","enrollment":52},{"nctId":"NCT00116415","phase":"NA","title":"DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-03","conditions":"HIV Infections, AIDS","enrollment":65},{"nctId":"NCT00207168","phase":"PHASE4","title":"To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-04","conditions":"AIDS","enrollment":120},{"nctId":"NCT00091936","phase":"NA","title":"Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-08","conditions":"HIV Infections, Tuberculosis","enrollment":592},{"nctId":"NCT00135382","phase":"PHASE3","title":"Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-06","conditions":"HIV Infections","enrollment":254},{"nctId":"NCT00332306","phase":"PHASE3","title":"Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2006-06","conditions":"Tuberculosis, Human Immunodeficiency Virus Infections","enrollment":180},{"nctId":"NCT00256828","phase":"PHASE4","title":"Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV","status":"COMPLETED","sponsor":"Clinical Trial Agency of HIV Study Group","startDate":"2004-06","conditions":"HIV Infections","enrollment":360},{"nctId":"NCT00080522","phase":"NA","title":"Strategies for Delivering Anti-HIV Therapy in South Africa","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":813},{"nctId":"NCT00158470","phase":"PHASE3","title":"Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2003-09","conditions":"HIV Infection","enrollment":100},{"nctId":"NCT00214435","phase":"PHASE4","title":"Once Daily 3TC, Efavirenz and ddI for HIV Infection","status":"UNKNOWN","sponsor":"407 Doctors","startDate":"2004-05","conditions":"HIV Infection, AIDS","enrollment":120},{"nctId":"NCT00002234","phase":"PHASE2","title":"Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT00005000","phase":"PHASE4","title":"Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs","status":"UNKNOWN","sponsor":"Agouron Pharmaceuticals","startDate":"1999-12","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00005018","phase":"PHASE4","title":"Safety and Effectiveness of a Combination Anti-HIV Drug Treatment","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-07","conditions":"HIV Infections","enrollment":150}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"ISOSPORIASIS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"didanosine + lamivudine + efavirenz","genericName":"didanosine + lamivudine + efavirenz","companyName":"Clinical Trial Agency of HIV Study Group","companyId":"clinical-trial-agency-of-hiv-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes required for viral reproduction. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}